Aradigm Corp (ARDM): Juergen Kurt Froehlich , Chief Medical Officer of Aradigm Corp sold 333 shares on Jun 21, 2016. The Insider selling transaction was reported by the company on Jun 23, 2016 to the Securities and Exchange Commission. The shares were sold at $4.45 per share for a total value of $1,481.85 , the company said in a SEC Form 4 Filing.
Aradigm Corporation: On Tuesday, Jun 21, 2016 heightened volatility was witnessed in Aradigm Corporation which led to swings in the share price. The shares opened for trading at $4.4 and hit $4.5 on the upside , eventually ending the session at $4.495, with a gain of 1.01% or 0.0449 points. The heightened volatility saw the trading volume jump to 3,494 shares. The 52-week high of the share price is $7.9 and the company has a market cap of $67 M . The 52-week low of the share price is at $2.6.
Aradigm Corporation is a pharmaceutical company. The Company is focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company’s lead product candidate is Pulmaquin which is in Phase III clinical trials. The Company also invested on AERx pulmonary drug delivery platform and other technologies. The Company’s partnered programs under development include Inhaled Ciprofloxacin. The Company is also developing Smoking Cessation Therapy (ARD-1600 Inhaled Nicotine) program. Its lead development candidates are the Company’s formulations of the potent antibiotic ciprofloxacin (Pulmaquin (ARD-3150) and Lipoquin (ARD-3100)) that are delivered by inhalation for the management of infections associated with severe respiratory diseases such as non-cystic fibrosis bronchiectasis (BE) and cystic fibrosis (CF).